CTKB — Cytek Biosciences, Inc.

Summary of Cytek Biosciences Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $52.3 million, a 2% increase year-over-year (YoY).
• Product Revenue: Decreased by 4% YoY, primarily due to a 26% decline in EMEA, offset by 19% growth in APAC.
• Service Revenue: Grew 19% YoY, driven by an expanding installed base and increased usage.
• Reagent Revenue: Achieved 21% growth YoY, marking its highest quarterly revenue.
• Gross Profit: $27.6 million, a 5% decrease YoY; gross margin at 53%, down from 56% YoY.
• Operating Loss: $9.2 million, compared to a $4.2 million loss in Q3 2024.
• Net Loss: $5.5 million, down from a net income of $0.9 million YoY.
• Adjusted EBITDA: Declined to $2.5 million from $7.6 million YoY.
• Free Cash Flow: Slightly negative at -$0.3 million; total cash and marketable securities at $261.7 million.

2. Strategic Updates and Business Highlights:

• Strong growth in the Asia Pacific region, with double-digit gains across instruments, reagents, and services.
• The U.S. market showed stabilization in instrument revenues, with flat performance YoY.
• EMEA faced significant challenges, particularly in academic and government sectors.
• Launched the Aurora Evo Analyzer, which received positive reception, contributing to a 12% growth in instrument revenue from pharma and biotech customers.
• Expanded European headquarters in Amsterdam to enhance operational efficiency and customer service.
• Cytek Cloud user base grew over 40% in 2025, reaching more than 22,600 users.

3. Forward Guidance and Outlook:

• Reaffirmed full-year 2025 revenue guidance of $196 million to $205 million.
• Anticipates continued growth in service and reagent businesses, with a typical Q4 budget flush expected from biopharma customers.
• Expects stabilization in the U.S. market and ongoing challenges in EMEA.

4. Bad News, Challenges, or Points of Concern:

• EMEA region experienced a 28% decline in revenue, primarily due to reduced instrument sales to academic and government customers.
• U.S. academic and government demand remains under pressure, with no signs of significant improvement expected.
• Increased operating expenses, particularly in general and administrative costs due to legal expenses and a non-recurring write-off.
• Declining gross profit margins due to higher costs and lower product revenues.

5. Notable Q&A Insights:

• The Aurora Evo product launch is expected to drive future growth, with features tailored for pharma and biotech customers.
• Conversations with customers indicate a cautious but positive outlook for instrument spending in 2026, particularly from biopharma.
• The company is focused on improving reagent capture rates through operational efficiencies and expanding its reagent portfolio.
• Management remains optimistic about the potential for M&A opportunities while balancing share repurchase strategies with free cash flow.

Overall, Cytek Biosciences reported modest revenue growth in Q3 2025, driven by strong performance in the Asia Pacific region and recurring revenue streams, while facing challenges in the EMEA market and academic sectors. The company maintains a positive outlook for the remainder of the year, supported by strategic initiatives and product launches.